#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=This scheme, sometimes referred to as peptides-on-plasmids, differs in two important ways from the phage display methods.
1-1	0-4	This	_	_	
1-2	5-11	scheme	_	_	
1-3	11-12	,	_	_	
1-4	13-22	sometimes	_	_	
1-5	23-31	referred	_	_	
1-6	32-34	to	_	_	
1-7	35-37	as	_	_	
1-8	38-58	peptides-on-plasmids	_	_	
1-9	58-59	,	_	_	
1-10	60-67	differs	_	_	
1-11	68-70	in	_	_	
1-12	71-74	two	_	_	
1-13	75-84	important	_	_	
1-14	85-89	ways	_	_	
1-15	90-94	from	_	_	
1-16	95-98	the	_	_	
1-17	99-104	phage	_	_	
1-18	105-112	display	_	_	
1-19	113-120	methods	_	_	
1-20	120-121	.	_	_	

#Text=First, the peptides are attached to the C-terminus of the fusion protein, resulting in the display of the library members as peptides having free carboxy termini.
2-1	122-127	First	_	_	
2-2	127-128	,	_	_	
2-3	129-132	the	_	_	
2-4	133-141	peptides	_	_	
2-5	142-145	are	_	_	
2-6	146-154	attached	_	_	
2-7	155-157	to	_	_	
2-8	158-161	the	_	_	
2-9	162-172	C-terminus	_	_	
2-10	173-175	of	_	_	
2-11	176-179	the	_	_	
2-12	180-186	fusion	_	_	
2-13	187-194	protein	_	_	
2-14	194-195	,	_	_	
2-15	196-205	resulting	_	_	
2-16	206-208	in	_	_	
2-17	209-212	the	_	_	
2-18	213-220	display	_	_	
2-19	221-223	of	_	_	
2-20	224-227	the	_	_	
2-21	228-235	library	_	_	
2-22	236-243	members	_	_	
2-23	244-246	as	_	_	
2-24	247-255	peptides	_	_	
2-25	256-262	having	_	_	
2-26	263-267	free	_	_	
2-27	268-275	carboxy	_	_	
2-28	276-283	termini	_	_	
2-29	283-284	.	_	_	

#Text=Both of the filamentous phage coat proteins, pIII and pVIII, are anchored to the phage through their C-termini, and the guest peptides are placed into the outward-extending N-terminal domains.
3-1	285-289	Both	_	_	
3-2	290-292	of	_	_	
3-3	293-296	the	_	_	
3-4	297-308	filamentous	_	_	
3-5	309-314	phage	_	_	
3-6	315-319	coat	_	_	
3-7	320-328	proteins	_	_	
3-8	328-329	,	_	_	
3-9	330-334	pIII	_	_	
3-10	335-338	and	_	_	
3-11	339-344	pVIII	_	_	
3-12	344-345	,	_	_	
3-13	346-349	are	_	_	
3-14	350-358	anchored	_	_	
3-15	359-361	to	_	_	
3-16	362-365	the	_	_	
3-17	366-371	phage	_	_	
3-18	372-379	through	_	_	
3-19	380-385	their	_	_	
3-20	386-395	C-termini	_	_	
3-21	395-396	,	_	_	
3-22	397-400	and	_	_	
3-23	401-404	the	_	_	
3-24	405-410	guest	_	_	
3-25	411-419	peptides	_	_	
3-26	420-423	are	_	_	
3-27	424-430	placed	_	_	
3-28	431-435	into	_	_	
3-29	436-439	the	_	_	
3-30	440-457	outward-extending	_	_	
3-31	458-468	N-terminal	_	_	
3-32	469-476	domains	_	_	
3-33	476-477	.	_	_	

#Text=In some designs, the phage-displayed peptides are presented right at the amino terminus of the fusion protein.
4-1	478-480	In	_	_	
4-2	481-485	some	_	_	
4-3	486-493	designs	_	_	
4-4	493-494	,	_	_	
4-5	495-498	the	_	_	
4-6	499-514	phage-displayed	_	_	
4-7	515-523	peptides	_	_	
4-8	524-527	are	_	_	
4-9	528-537	presented	_	_	
4-10	538-543	right	_	_	
4-11	544-546	at	_	_	
4-12	547-550	the	_	_	
4-13	551-556	amino	_	_	
4-14	557-565	terminus	_	_	
4-15	566-568	of	_	_	
4-16	569-572	the	_	_	
4-17	573-579	fusion	_	_	
4-18	580-587	protein	_	_	
4-19	587-588	.	_	_	

#Text=(Cwirla, et al. (1990) Proc.
5-1	589-590	(	_	_	
5-2	590-596	Cwirla	_	_	
5-3	596-597	,	_	_	
5-4	598-600	et	_	_	
5-5	601-603	al	_	_	
5-6	603-604	.	_	_	
5-7	605-606	(	_	_	
5-8	606-610	1990	_	_	
5-9	610-611	)	_	_	
5-10	612-616	Proc	_	_	
5-11	616-617	.	_	_	

#Text=Natl.
6-1	618-622	Natl	_	_	
6-2	622-623	.	_	_	

#Text=Acad.
7-1	624-628	Acad	_	_	
7-2	628-629	.	_	_	

#Text=Sci.
8-1	630-633	Sci	_	_	
8-2	633-634	.	_	_	

#Text=U.S.A. 87, 6378-6382) A second difference is the set of biological biases affecting the population of peptides actually present in the libraries.
9-1	635-640	U.S.A	_	_	
9-2	640-641	.	_	_	
9-3	642-644	87	_	_	
9-4	644-645	,	_	_	
9-5	646-650	6378	_	_	
9-6	650-651	-	_	_	
9-7	651-655	6382	_	_	
9-8	655-656	)	_	_	
9-9	657-658	A	_	_	
9-10	659-665	second	_	_	
9-11	666-676	difference	_	_	
9-12	677-679	is	_	_	
9-13	680-683	the	_	_	
9-14	684-687	set	_	_	
9-15	688-690	of	_	_	
9-16	691-701	biological	_	_	
9-17	702-708	biases	_	_	
9-18	709-718	affecting	_	_	
9-19	719-722	the	_	_	
9-20	723-733	population	_	_	
9-21	734-736	of	_	_	
9-22	737-745	peptides	_	_	
9-23	746-754	actually	_	_	
9-24	755-762	present	_	_	
9-25	763-765	in	_	_	
9-26	766-769	the	_	_	
9-27	770-779	libraries	_	_	
9-28	779-780	.	_	_	

#Text=The LacI fusion molecules are confined to the cytoplasm of the host cells.
10-1	781-784	The	_	_	
10-2	785-789	LacI	_	_	
10-3	790-796	fusion	_	_	
10-4	797-806	molecules	_	_	
10-5	807-810	are	_	_	
10-6	811-819	confined	_	_	
10-7	820-822	to	_	_	
10-8	823-826	the	_	_	
10-9	827-836	cytoplasm	_	_	
10-10	837-839	of	_	_	
10-11	840-843	the	_	_	
10-12	844-848	host	_	_	
10-13	849-854	cells	_	_	
10-14	854-855	.	_	_	

#Text=The phage coat fusions are exposed briefly to the cytoplasm during translation but are rapidly secreted through the inner membrane into the periplasmic compartment, remaining anchored in the membrane by their C-terminal hydrophobic domains, with the N-termini, containing the peptides, protruding into the periplasm while awaiting assembly into phage particles.
11-1	856-859	The	_	_	
11-2	860-865	phage	_	_	
11-3	866-870	coat	_	_	
11-4	871-878	fusions	_	_	
11-5	879-882	are	_	_	
11-6	883-890	exposed	_	_	
11-7	891-898	briefly	_	_	
11-8	899-901	to	_	_	
11-9	902-905	the	_	_	
11-10	906-915	cytoplasm	_	_	
11-11	916-922	during	_	_	
11-12	923-934	translation	_	_	
11-13	935-938	but	_	_	
11-14	939-942	are	_	_	
11-15	943-950	rapidly	_	_	
11-16	951-959	secreted	_	_	
11-17	960-967	through	_	_	
11-18	968-971	the	_	_	
11-19	972-977	inner	_	_	
11-20	978-986	membrane	_	_	
11-21	987-991	into	_	_	
11-22	992-995	the	_	_	
11-23	996-1007	periplasmic	_	_	
11-24	1008-1019	compartment	_	_	
11-25	1019-1020	,	_	_	
11-26	1021-1030	remaining	_	_	
11-27	1031-1039	anchored	_	_	
11-28	1040-1042	in	_	_	
11-29	1043-1046	the	_	_	
11-30	1047-1055	membrane	_	_	
11-31	1056-1058	by	_	_	
11-32	1059-1064	their	_	_	
11-33	1065-1075	C-terminal	_	_	
11-34	1076-1087	hydrophobic	_	_	
11-35	1088-1095	domains	_	_	
11-36	1095-1096	,	_	_	
11-37	1097-1101	with	_	_	
11-38	1102-1105	the	_	_	
11-39	1106-1115	N-termini	_	_	
11-40	1115-1116	,	_	_	
11-41	1117-1127	containing	_	_	
11-42	1128-1131	the	_	_	
11-43	1132-1140	peptides	_	_	
11-44	1140-1141	,	_	_	
11-45	1142-1152	protruding	_	_	
11-46	1153-1157	into	_	_	
11-47	1158-1161	the	_	_	
11-48	1162-1171	periplasm	_	_	
11-49	1172-1177	while	_	_	
11-50	1178-1186	awaiting	_	_	
11-51	1187-1195	assembly	_	_	
11-52	1196-1200	into	_	_	
11-53	1201-1206	phage	_	_	
11-54	1207-1216	particles	_	_	
11-55	1216-1217	.	_	_	

#Text=The peptides in the LacI and phage libraries may differ significantly as a result of their exposure to different proteolytic activities.
12-1	1218-1221	The	_	_	
12-2	1222-1230	peptides	_	_	
12-3	1231-1233	in	_	_	
12-4	1234-1237	the	_	_	
12-5	1238-1242	LacI	_	_	
12-6	1243-1246	and	_	_	
12-7	1247-1252	phage	_	_	
12-8	1253-1262	libraries	_	_	
12-9	1263-1266	may	_	_	
12-10	1267-1273	differ	_	_	
12-11	1274-1287	significantly	_	_	
12-12	1288-1290	as	_	_	
12-13	1291-1292	a	_	_	
12-14	1293-1299	result	_	_	
12-15	1300-1302	of	_	_	
12-16	1303-1308	their	_	_	
12-17	1309-1317	exposure	_	_	
12-18	1318-1320	to	_	_	
12-19	1321-1330	different	_	_	
12-20	1331-1342	proteolytic	_	_	
12-21	1343-1353	activities	_	_	
12-22	1353-1354	.	_	_	

#Text=The phage coat proteins require transport across the inner membrane and signal peptidase processing as a prelude to incorporation into phage.
13-1	1355-1358	The	_	_	
13-2	1359-1364	phage	_	_	
13-3	1365-1369	coat	_	_	
13-4	1370-1378	proteins	_	_	
13-5	1379-1386	require	_	_	
13-6	1387-1396	transport	_	_	
13-7	1397-1403	across	_	_	
13-8	1404-1407	the	_	_	
13-9	1408-1413	inner	_	_	
13-10	1414-1422	membrane	_	_	
13-11	1423-1426	and	_	_	
13-12	1427-1433	signal	_	_	
13-13	1434-1443	peptidase	_	_	
13-14	1444-1454	processing	_	_	
13-15	1455-1457	as	_	_	
13-16	1458-1459	a	_	_	
13-17	1460-1467	prelude	_	_	
13-18	1468-1470	to	_	_	
13-19	1471-1484	incorporation	_	_	
13-20	1485-1489	into	_	_	
13-21	1490-1495	phage	_	_	
13-22	1495-1496	.	_	_	

#Text=Certain peptides exert a deleterious effect on these processes and are underrepresented in the libraries (Gallop et al. (1994) J.
14-1	1497-1504	Certain	_	_	
14-2	1505-1513	peptides	_	_	
14-3	1514-1519	exert	_	_	
14-4	1520-1521	a	_	_	
14-5	1522-1533	deleterious	_	_	
14-6	1534-1540	effect	_	_	
14-7	1541-1543	on	_	_	
14-8	1544-1549	these	_	_	
14-9	1550-1559	processes	_	_	
14-10	1560-1563	and	_	_	
14-11	1564-1567	are	_	_	
14-12	1568-1584	underrepresented	_	_	
14-13	1585-1587	in	_	_	
14-14	1588-1591	the	_	_	
14-15	1592-1601	libraries	_	_	
14-16	1602-1603	(	_	_	
14-17	1603-1609	Gallop	_	_	
14-18	1610-1612	et	_	_	
14-19	1613-1615	al	_	_	
14-20	1615-1616	.	_	_	
14-21	1617-1618	(	_	_	
14-22	1618-1622	1994	_	_	
14-23	1622-1623	)	_	_	
14-24	1624-1625	J	_	_	
14-25	1625-1626	.	_	_	

#Text=Med.
15-1	1627-1630	Med	_	_	
15-2	1630-1631	.	_	_	

#Text=Chem. 37(9):1233-1251).
16-1	1632-1636	Chem	_	_	
16-2	1636-1637	.	_	_	
16-3	1638-1640	37	_	_	
16-4	1640-1641	(	_	_	
16-5	1641-1642	9	_	_	
16-6	1642-1643	)	_	_	
16-7	1643-1644	:	_	_	
16-8	1644-1648	1233	_	_	
16-9	1648-1649	-	_	_	
16-10	1649-1653	1251	_	_	
16-11	1653-1654	)	_	_	
16-12	1654-1655	.	_	_	

#Text=These particular biases are not a factor in the LacI display system.
17-1	1656-1661	These	_	_	
17-2	1662-1672	particular	_	_	
17-3	1673-1679	biases	_	_	
17-4	1680-1683	are	_	_	
17-5	1684-1687	not	_	_	
17-6	1688-1689	a	_	_	
17-7	1690-1696	factor	_	_	
17-8	1697-1699	in	_	_	
17-9	1700-1703	the	_	_	
17-10	1704-1708	LacI	_	_	
17-11	1709-1716	display	_	_	
17-12	1717-1723	system	_	_	
17-13	1723-1724	.	_	_	

#Text=The number of small peptides available in recombinant random libraries is enormous.
18-1	1725-1728	The	_	_	
18-2	1729-1735	number	_	_	
18-3	1736-1738	of	_	_	
18-4	1739-1744	small	_	_	
18-5	1745-1753	peptides	_	_	
18-6	1754-1763	available	_	_	
18-7	1764-1766	in	_	_	
18-8	1767-1778	recombinant	_	_	
18-9	1779-1785	random	_	_	
18-10	1786-1795	libraries	_	_	
18-11	1796-1798	is	_	_	
18-12	1799-1807	enormous	_	_	
18-13	1807-1808	.	_	_	

#Text=Libraries of 10.sup.7 -10.sup.9 independent clones are routinely prepared.
19-1	1809-1818	Libraries	_	_	
19-2	1819-1821	of	_	_	
19-3	1822-1824	10	_	_	
19-4	1824-1825	.	_	_	
19-5	1825-1828	sup	_	_	
19-6	1828-1830	.7	_	_	
19-7	1831-1832	-	_	_	
19-8	1832-1834	10	_	_	
19-9	1834-1835	.	_	_	
19-10	1835-1838	sup	_	_	
19-11	1838-1840	.9	_	_	
19-12	1841-1852	independent	_	_	
19-13	1853-1859	clones	_	_	
19-14	1860-1863	are	_	_	
19-15	1864-1873	routinely	_	_	
19-16	1874-1882	prepared	_	_	
19-17	1882-1883	.	_	_	

#Text=Libraries as large as 10.sup.11 recombinants have been created, but this size approaches the practical limit for clone libraries.
20-1	1884-1893	Libraries	_	_	
20-2	1894-1896	as	_	_	
20-3	1897-1902	large	_	_	
20-4	1903-1905	as	_	_	
20-5	1906-1908	10	_	_	
20-6	1908-1909	.	_	_	
20-7	1909-1912	sup	_	_	
20-8	1912-1915	.11	_	_	
20-9	1916-1928	recombinants	_	_	
20-10	1929-1933	have	_	_	
20-11	1934-1938	been	_	_	
20-12	1939-1946	created	_	_	
20-13	1946-1947	,	_	_	
20-14	1948-1951	but	_	_	
20-15	1952-1956	this	_	_	
20-16	1957-1961	size	_	_	
20-17	1962-1972	approaches	_	_	
20-18	1973-1976	the	_	_	
20-19	1977-1986	practical	_	_	
20-20	1987-1992	limit	_	_	
20-21	1993-1996	for	_	_	
20-22	1997-2002	clone	_	_	
20-23	2003-2012	libraries	_	_	
20-24	2012-2013	.	_	_	

#Text=This limitation in library size occurs at the step of transforming the DNA containing randomized segments intothe host bacterial cells.
21-1	2014-2018	This	_	_	
21-2	2019-2029	limitation	_	_	
21-3	2030-2032	in	_	_	
21-4	2033-2040	library	_	_	
21-5	2041-2045	size	_	_	
21-6	2046-2052	occurs	_	_	
21-7	2053-2055	at	_	_	
21-8	2056-2059	the	_	_	
21-9	2060-2064	step	_	_	
21-10	2065-2067	of	_	_	
21-11	2068-2080	transforming	_	_	
21-12	2081-2084	the	_	_	
21-13	2085-2088	DNA	_	_	
21-14	2089-2099	containing	_	_	
21-15	2100-2110	randomized	_	_	
21-16	2111-2119	segments	_	_	
21-17	2120-2127	intothe	_	_	
21-18	2128-2132	host	_	_	
21-19	2133-2142	bacterial	_	_	
21-20	2143-2148	cells	_	_	
21-21	2148-2149	.	_	_	

#Text=To circumvent this limitation, an in vitro system based on the display of nascent peptides in polysome complexes has recently been developed.
22-1	2150-2152	To	_	_	
22-2	2153-2163	circumvent	_	_	
22-3	2164-2168	this	_	_	
22-4	2169-2179	limitation	_	_	
22-5	2179-2180	,	_	_	
22-6	2181-2183	an	_	_	
22-7	2184-2186	in	_	_	
22-8	2187-2192	vitro	_	_	
22-9	2193-2199	system	_	_	
22-10	2200-2205	based	_	_	
22-11	2206-2208	on	_	_	
22-12	2209-2212	the	_	_	
22-13	2213-2220	display	_	_	
22-14	2221-2223	of	_	_	
22-15	2224-2231	nascent	_	_	
22-16	2232-2240	peptides	_	_	
22-17	2241-2243	in	_	_	
22-18	2244-2252	polysome	_	_	
22-19	2253-2262	complexes	_	_	
22-20	2263-2266	has	_	_	
22-21	2267-2275	recently	_	_	
22-22	2276-2280	been	_	_	
22-23	2281-2290	developed	_	_	
22-24	2290-2291	.	_	_	

#Text=This display library method has the potential of producing libraries 3-6 orders of magnitude larger than the currently available phage/phagemid or plasmid libraries.
23-1	2292-2296	This	*[1]	25-5[2_1]	
23-2	2297-2304	display	*[1]	_	
23-3	2305-2312	library	*[1]	_	
23-4	2313-2319	method	*[1]	_	
23-5	2320-2323	has	_	_	
23-6	2324-2327	the	_	_	
23-7	2328-2337	potential	_	_	
23-8	2338-2340	of	_	_	
23-9	2341-2350	producing	_	_	
23-10	2351-2360	libraries	_	_	
23-11	2361-2362	3	_	_	
23-12	2362-2363	-	_	_	
23-13	2363-2364	6	_	_	
23-14	2365-2371	orders	_	_	
23-15	2372-2374	of	_	_	
23-16	2375-2384	magnitude	_	_	
23-17	2385-2391	larger	_	_	
23-18	2392-2396	than	_	_	
23-19	2397-2400	the	_	_	
23-20	2401-2410	currently	_	_	
23-21	2411-2420	available	_	_	
23-22	2421-2426	phage	_	_	
23-23	2426-2427	/	_	_	
23-24	2427-2435	phagemid	_	_	
23-25	2436-2438	or	_	_	
23-26	2439-2446	plasmid	_	_	
23-27	2447-2456	libraries	_	_	
23-28	2456-2457	.	_	_	

#Text=Furthermore, the construction of the libraries, expression of the peptides, and screening, is done in an entirely cell-free format.
24-1	2458-2469	Furthermore	_	_	
24-2	2469-2470	,	_	_	
24-3	2471-2474	the	_	_	
24-4	2475-2487	construction	_	_	
24-5	2488-2490	of	_	_	
24-6	2491-2494	the	_	_	
24-7	2495-2504	libraries	_	_	
24-8	2504-2505	,	_	_	
24-9	2506-2516	expression	_	_	
24-10	2517-2519	of	_	_	
24-11	2520-2523	the	_	_	
24-12	2524-2532	peptides	_	_	
24-13	2532-2533	,	_	_	
24-14	2534-2537	and	_	_	
24-15	2538-2547	screening	_	_	
24-16	2547-2548	,	_	_	
24-17	2549-2551	is	_	_	
24-18	2552-2556	done	_	_	
24-19	2557-2559	in	_	_	
24-20	2560-2562	an	_	_	
24-21	2563-2571	entirely	_	_	
24-22	2572-2581	cell-free	_	_	
24-23	2582-2588	format	_	_	
24-24	2588-2589	.	_	_	

#Text=In one application of this method (Gallop et al. (1994) J.
25-1	2590-2592	In	_	_	
25-2	2593-2596	one	_	_	
25-3	2597-2608	application	_	_	
25-4	2609-2611	of	_	_	
25-5	2612-2616	this	*[2]	_	
25-6	2617-2623	method	*[2]	_	
25-7	2624-2625	(	_	_	
25-8	2625-2631	Gallop	_	_	
25-9	2632-2634	et	_	_	
25-10	2635-2637	al	_	_	
25-11	2637-2638	.	_	_	
25-12	2639-2640	(	_	_	
25-13	2640-2644	1994	_	_	
25-14	2644-2645	)	_	_	
25-15	2646-2647	J	_	_	
25-16	2647-2648	.	_	_	

#Text=Med.
26-1	2649-2652	Med	_	_	
26-2	2652-2653	.	_	_	

#Text=Chem. 37(9):1233-1251), a molecular DNA library encoding 10.sup.12 decapeptides was constructed and the library expressed in an E. coli S30 in vitro coupled transcription/translation system.
27-1	2654-2658	Chem	_	_	
27-2	2658-2659	.	_	_	
27-3	2660-2662	37	_	_	
27-4	2662-2663	(	_	_	
27-5	2663-2664	9	_	_	
27-6	2664-2665	)	_	_	
27-7	2665-2666	:	_	_	
27-8	2666-2670	1233	_	_	
27-9	2670-2671	-	_	_	
27-10	2671-2675	1251	_	_	
27-11	2675-2676	)	_	_	
27-12	2676-2677	,	_	_	
27-13	2678-2679	a	_	_	
27-14	2680-2689	molecular	_	_	
27-15	2690-2693	DNA	_	_	
27-16	2694-2701	library	_	_	
27-17	2702-2710	encoding	_	_	
27-18	2711-2713	10	_	_	
27-19	2713-2714	.	_	_	
27-20	2714-2717	sup	_	_	
27-21	2717-2720	.12	_	_	
27-22	2721-2733	decapeptides	_	_	
27-23	2734-2737	was	_	_	
27-24	2738-2749	constructed	_	_	
27-25	2750-2753	and	_	_	
27-26	2754-2757	the	_	_	
27-27	2758-2765	library	_	_	
27-28	2766-2775	expressed	_	_	
27-29	2776-2778	in	_	_	
27-30	2779-2781	an	_	_	
27-31	2782-2783	E	_	_	
27-32	2783-2784	.	_	_	
27-33	2785-2789	coli	_	_	
27-34	2790-2793	S30	_	_	
27-35	2794-2796	in	_	_	
27-36	2797-2802	vitro	_	_	
27-37	2803-2810	coupled	_	_	
27-38	2811-2824	transcription	_	_	
27-39	2824-2825	/	_	_	
27-40	2825-2836	translation	_	_	
27-41	2837-2843	system	_	_	
27-42	2843-2844	.	_	_	

#Text=Conditions were chosen to stall the ribosomes on the mRNA, causing the accumulation of a substantial proportion of the RNA in polysomes and yielding complexes containing nascent peptides still linked to their encoding RNA.
28-1	2845-2855	Conditions	_	_	
28-2	2856-2860	were	_	_	
28-3	2861-2867	chosen	_	_	
28-4	2868-2870	to	_	_	
28-5	2871-2876	stall	_	_	
28-6	2877-2880	the	_	_	
28-7	2881-2890	ribosomes	_	_	
28-8	2891-2893	on	_	_	
28-9	2894-2897	the	_	_	
28-10	2898-2902	mRNA	_	_	
28-11	2902-2903	,	_	_	
28-12	2904-2911	causing	_	_	
28-13	2912-2915	the	_	_	
28-14	2916-2928	accumulation	_	_	
28-15	2929-2931	of	_	_	
28-16	2932-2933	a	_	_	
28-17	2934-2945	substantial	_	_	
28-18	2946-2956	proportion	_	_	
28-19	2957-2959	of	_	_	
28-20	2960-2963	the	_	_	
28-21	2964-2967	RNA	_	_	
28-22	2968-2970	in	_	_	
28-23	2971-2980	polysomes	_	_	
28-24	2981-2984	and	_	_	
28-25	2985-2993	yielding	_	_	
28-26	2994-3003	complexes	_	_	
28-27	3004-3014	containing	_	_	
28-28	3015-3022	nascent	_	_	
28-29	3023-3031	peptides	_	_	
28-30	3032-3037	still	_	_	
28-31	3038-3044	linked	_	_	
28-32	3045-3047	to	_	_	
28-33	3048-3053	their	_	_	
28-34	3054-3062	encoding	_	_	
28-35	3063-3066	RNA	_	_	
28-36	3066-3067	.	_	_	

#Text=The polysomes are sufficiently robust to be affinity purified on immobilized receptors in much the same way as the more conventional recombinant peptide display libraries are screened.
29-1	3068-3071	The	_	_	
29-2	3072-3081	polysomes	_	_	
29-3	3082-3085	are	_	_	
29-4	3086-3098	sufficiently	_	_	
29-5	3099-3105	robust	_	_	
29-6	3106-3108	to	_	_	
29-7	3109-3111	be	_	_	
29-8	3112-3120	affinity	_	_	
29-9	3121-3129	purified	_	_	
29-10	3130-3132	on	_	_	
29-11	3133-3144	immobilized	_	_	
29-12	3145-3154	receptors	_	_	
29-13	3155-3157	in	_	_	
29-14	3158-3162	much	_	_	
29-15	3163-3166	the	_	_	
29-16	3167-3171	same	_	_	
29-17	3172-3175	way	_	_	
29-18	3176-3178	as	_	_	
29-19	3179-3182	the	_	_	
29-20	3183-3187	more	_	_	
29-21	3188-3200	conventional	_	_	
29-22	3201-3212	recombinant	_	_	
29-23	3213-3220	peptide	_	_	
29-24	3221-3228	display	_	_	
29-25	3229-3238	libraries	_	_	
29-26	3239-3242	are	_	_	
29-27	3243-3251	screened	_	_	
29-28	3251-3252	.	_	_	

#Text=RNA from the bound complexes is recovered, converted to cDNA, and amplified by PCR to produce a template for the next round of synthesis and screening.
30-1	3253-3256	RNA	_	_	
30-2	3257-3261	from	_	_	
30-3	3262-3265	the	_	_	
30-4	3266-3271	bound	_	_	
30-5	3272-3281	complexes	_	_	
30-6	3282-3284	is	_	_	
30-7	3285-3294	recovered	_	_	
30-8	3294-3295	,	_	_	
30-9	3296-3305	converted	_	_	
30-10	3306-3308	to	_	_	
30-11	3309-3313	cDNA	_	_	
30-12	3313-3314	,	_	_	
30-13	3315-3318	and	_	_	
30-14	3319-3328	amplified	_	_	
30-15	3329-3331	by	_	_	
30-16	3332-3335	PCR	_	_	
30-17	3336-3338	to	_	_	
30-18	3339-3346	produce	_	_	
30-19	3347-3348	a	_	_	
30-20	3349-3357	template	_	_	
30-21	3358-3361	for	_	_	
30-22	3362-3365	the	_	_	
30-23	3366-3370	next	_	_	
30-24	3371-3376	round	_	_	
30-25	3377-3379	of	_	_	
30-26	3380-3389	synthesis	_	_	
30-27	3390-3393	and	_	_	
30-28	3394-3403	screening	_	_	
30-29	3403-3404	.	_	_	

#Text=The polysome display method can be coupled to the phage display system.
31-1	3405-3408	The	_	_	
31-2	3409-3417	polysome	_	_	
31-3	3418-3425	display	_	_	
31-4	3426-3432	method	_	_	
31-5	3433-3436	can	_	_	
31-6	3437-3439	be	_	_	
31-7	3440-3447	coupled	_	_	
31-8	3448-3450	to	_	_	
31-9	3451-3454	the	_	_	
31-10	3455-3460	phage	_	_	
31-11	3461-3468	display	_	_	
31-12	3469-3475	system	_	_	
31-13	3475-3476	.	_	_	

#Text=Following several rounds of screening, cDNA from the enriched pool of polysomes was cloned into a phagemid vector.
32-1	3477-3486	Following	_	_	
32-2	3487-3494	several	_	_	
32-3	3495-3501	rounds	_	_	
32-4	3502-3504	of	_	_	
32-5	3505-3514	screening	_	_	
32-6	3514-3515	,	_	_	
32-7	3516-3520	cDNA	_	_	
32-8	3521-3525	from	_	_	
32-9	3526-3529	the	_	_	
32-10	3530-3538	enriched	_	_	
32-11	3539-3543	pool	_	_	
32-12	3544-3546	of	_	_	
32-13	3547-3556	polysomes	_	_	
32-14	3557-3560	was	_	_	
32-15	3561-3567	cloned	_	_	
32-16	3568-3572	into	_	_	
32-17	3573-3574	a	_	_	
32-18	3575-3583	phagemid	_	_	
32-19	3584-3590	vector	_	_	
32-20	3590-3591	.	_	_	

#Text=This vector serves as both a peptide expression vector, displaying peptides fused to the coat proteins, and as a DNA sequencing vector for peptide identification.
33-1	3592-3596	This	_	_	
33-2	3597-3603	vector	_	_	
33-3	3604-3610	serves	_	_	
33-4	3611-3613	as	_	_	
33-5	3614-3618	both	_	_	
33-6	3619-3620	a	_	_	
33-7	3621-3628	peptide	_	_	
33-8	3629-3639	expression	_	_	
33-9	3640-3646	vector	_	_	
33-10	3646-3647	,	_	_	
33-11	3648-3658	displaying	_	_	
33-12	3659-3667	peptides	_	_	
33-13	3668-3673	fused	_	_	
33-14	3674-3676	to	_	_	
33-15	3677-3680	the	_	_	
33-16	3681-3685	coat	_	_	
33-17	3686-3694	proteins	_	_	
33-18	3694-3695	,	_	_	
33-19	3696-3699	and	_	_	
33-20	3700-3702	as	_	_	
33-21	3703-3704	a	_	_	
33-22	3705-3708	DNA	_	_	
33-23	3709-3719	sequencing	_	_	
33-24	3720-3726	vector	_	_	
33-25	3727-3730	for	_	_	
33-26	3731-3738	peptide	_	_	
33-27	3739-3753	identification	_	_	
33-28	3753-3754	.	_	_	

#Text=By expressing the polysome-derived peptides on phage, one can either continue the affinity selection procedure in this format or assay the peptides on individual clones for binding activity in a phage ELISA, or for binding specificity in a completion phage ELISA (Barret, et al. (1992) Anal.
34-1	3755-3757	By	_	_	
34-2	3758-3768	expressing	_	_	
34-3	3769-3772	the	_	_	
34-4	3773-3789	polysome-derived	_	_	
34-5	3790-3798	peptides	_	_	
34-6	3799-3801	on	_	_	
34-7	3802-3807	phage	_	_	
34-8	3807-3808	,	_	_	
34-9	3809-3812	one	_	_	
34-10	3813-3816	can	_	_	
34-11	3817-3823	either	_	_	
34-12	3824-3832	continue	_	_	
34-13	3833-3836	the	_	_	
34-14	3837-3845	affinity	_	_	
34-15	3846-3855	selection	_	_	
34-16	3856-3865	procedure	_	_	
34-17	3866-3868	in	_	_	
34-18	3869-3873	this	_	_	
34-19	3874-3880	format	_	_	
34-20	3881-3883	or	_	_	
34-21	3884-3889	assay	_	_	
34-22	3890-3893	the	_	_	
34-23	3894-3902	peptides	_	_	
34-24	3903-3905	on	_	_	
34-25	3906-3916	individual	_	_	
34-26	3917-3923	clones	_	_	
34-27	3924-3927	for	_	_	
34-28	3928-3935	binding	_	_	
34-29	3936-3944	activity	_	_	
34-30	3945-3947	in	_	_	
34-31	3948-3949	a	_	_	
34-32	3950-3955	phage	_	_	
34-33	3956-3961	ELISA	_	_	
34-34	3961-3962	,	_	_	
34-35	3963-3965	or	_	_	
34-36	3966-3969	for	_	_	
34-37	3970-3977	binding	_	_	
34-38	3978-3989	specificity	_	_	
34-39	3990-3992	in	_	_	
34-40	3993-3994	a	_	_	
34-41	3995-4005	completion	_	_	
34-42	4006-4011	phage	_	_	
34-43	4012-4017	ELISA	_	_	
34-44	4018-4019	(	_	_	
34-45	4019-4025	Barret	_	_	
34-46	4025-4026	,	_	_	
34-47	4027-4029	et	_	_	
34-48	4030-4032	al	_	_	
34-49	4032-4033	.	_	_	
34-50	4034-4035	(	_	_	
34-51	4035-4039	1992	_	_	
34-52	4039-4040	)	_	_	
34-53	4041-4045	Anal	_	_	
34-54	4045-4046	.	_	_	

#Text=Biochem 204,357-364).
35-1	4047-4054	Biochem	_	_	
35-2	4055-4062	204,357	_	_	
35-3	4062-4063	-	_	_	
35-4	4063-4066	364	_	_	
35-5	4066-4067	)	_	_	
35-6	4067-4068	.	_	_	

#Text=To identify the sequences of the active peptides one sequences the DNA produced by the phagemid host.
36-1	4069-4071	To	_	_	
36-2	4072-4080	identify	_	_	
36-3	4081-4084	the	_	_	
36-4	4085-4094	sequences	_	_	
36-5	4095-4097	of	_	_	
36-6	4098-4101	the	_	_	
36-7	4102-4108	active	_	_	
36-8	4109-4117	peptides	_	_	
36-9	4118-4121	one	_	_	
36-10	4122-4131	sequences	_	_	
36-11	4132-4135	the	_	_	
36-12	4136-4139	DNA	_	_	
36-13	4140-4148	produced	_	_	
36-14	4149-4151	by	_	_	
36-15	4152-4155	the	_	_	
36-16	4156-4164	phagemid	_	_	
36-17	4165-4169	host	_	_	
36-18	4169-4170	.	_	_	

#Text=Secondary Screening of Polypeptides and Analogs
#Text=The high through-put assays described above can be followed by secondary screens in order to identify further biological activities which will, e.g., allow one skilled in the art to differentiate agonists from antagonists.
37-1	4171-4180	Secondary	_	_	
37-2	4181-4190	Screening	_	_	
37-3	4191-4193	of	_	_	
37-4	4194-4206	Polypeptides	_	_	
37-5	4207-4210	and	_	_	
37-6	4211-4218	Analogs	_	_	
37-7	4219-4222	The	_	_	
37-8	4223-4227	high	_	_	
37-9	4228-4239	through-put	_	_	
37-10	4240-4246	assays	_	_	
37-11	4247-4256	described	_	_	
37-12	4257-4262	above	_	_	
37-13	4263-4266	can	_	_	
37-14	4267-4269	be	_	_	
37-15	4270-4278	followed	_	_	
37-16	4279-4281	by	_	_	
37-17	4282-4291	secondary	_	_	
37-18	4292-4299	screens	_	_	
37-19	4300-4302	in	_	_	
37-20	4303-4308	order	_	_	
37-21	4309-4311	to	_	_	
37-22	4312-4320	identify	_	_	
37-23	4321-4328	further	_	_	
37-24	4329-4339	biological	_	_	
37-25	4340-4350	activities	_	_	
37-26	4351-4356	which	_	_	
37-27	4357-4361	will	_	_	
37-28	4361-4362	,	_	_	
37-29	4363-4366	e.g	_	_	
37-30	4366-4367	.	_	_	
37-31	4367-4368	,	_	_	
37-32	4369-4374	allow	_	_	
37-33	4375-4378	one	_	_	
37-34	4379-4386	skilled	_	_	
37-35	4387-4389	in	_	_	
37-36	4390-4393	the	_	_	
37-37	4394-4397	art	_	_	
37-38	4398-4400	to	_	_	
37-39	4401-4414	differentiate	_	_	
37-40	4415-4423	agonists	_	_	
37-41	4424-4428	from	_	_	
37-42	4429-4440	antagonists	_	_	
37-43	4440-4441	.	_	_	

#Text=The type of a secondary screen used will depend on the desired activity that needs to be tested.
38-1	4442-4445	The	_	_	
38-2	4446-4450	type	_	_	
38-3	4451-4453	of	_	_	
38-4	4454-4455	a	_	_	
38-5	4456-4465	secondary	_	_	
38-6	4466-4472	screen	_	_	
38-7	4473-4477	used	_	_	
38-8	4478-4482	will	_	_	
38-9	4483-4489	depend	_	_	
38-10	4490-4492	on	_	_	
38-11	4493-4496	the	_	_	
38-12	4497-4504	desired	_	_	
38-13	4505-4513	activity	_	_	
38-14	4514-4518	that	_	_	
38-15	4519-4524	needs	_	_	
38-16	4525-4527	to	_	_	
38-17	4528-4530	be	_	_	
38-18	4531-4537	tested	_	_	
38-19	4537-4538	.	_	_	

#Text=For example, an assay can be developed in which the ability to inhibit an interaction between a protein of interest and its respective ligand can be used to identify antagonists from a group of peptide fragments isolated though one of the primary screens described above.
39-1	4539-4542	For	_	_	
39-2	4543-4550	example	_	_	
39-3	4550-4551	,	_	_	
39-4	4552-4554	an	_	_	
39-5	4555-4560	assay	_	_	
39-6	4561-4564	can	_	_	
39-7	4565-4567	be	_	_	
39-8	4568-4577	developed	_	_	
39-9	4578-4580	in	_	_	
39-10	4581-4586	which	_	_	
39-11	4587-4590	the	_	_	
39-12	4591-4598	ability	_	_	
39-13	4599-4601	to	_	_	
39-14	4602-4609	inhibit	_	_	
39-15	4610-4612	an	_	_	
39-16	4613-4624	interaction	_	_	
39-17	4625-4632	between	_	_	
39-18	4633-4634	a	_	_	
39-19	4635-4642	protein	_	_	
39-20	4643-4645	of	_	_	
39-21	4646-4654	interest	_	_	
39-22	4655-4658	and	_	_	
39-23	4659-4662	its	_	_	
39-24	4663-4673	respective	_	_	
39-25	4674-4680	ligand	_	_	
39-26	4681-4684	can	_	_	
39-27	4685-4687	be	_	_	
39-28	4688-4692	used	_	_	
39-29	4693-4695	to	_	_	
39-30	4696-4704	identify	_	_	
39-31	4705-4716	antagonists	_	_	
39-32	4717-4721	from	_	_	
39-33	4722-4723	a	_	_	
39-34	4724-4729	group	_	_	
39-35	4730-4732	of	_	_	
39-36	4733-4740	peptide	_	_	
39-37	4741-4750	fragments	_	_	
39-38	4751-4759	isolated	_	_	
39-39	4760-4766	though	_	_	
39-40	4767-4770	one	_	_	
39-41	4771-4773	of	_	_	
39-42	4774-4777	the	_	_	
39-43	4778-4785	primary	_	_	
39-44	4786-4793	screens	_	_	
39-45	4794-4803	described	_	_	
39-46	4804-4809	above	_	_	
39-47	4809-4810	.	_	_	
